Atossa Therapeutics, Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics, Inc. Common Stock

Atossa Genetics Inc. (NASDAQ: ATOS) is developing locally-administered pharmaceuticals for pre-cancerous breast conditions and early stage breast cancer.

Aspire Capital Partners LLC

Keiretsu Forum Northwest

Excited to be participating in the Cantor Fitzgerald Healthcare conference today. Link to view the fireside chat with Dr. Quay is on the investor page of our website - https://lnkd.in/eJ7WFPZq

Looking forward to joining 14,000 biotech and pharma leaders in Boston next week.

Atossa to present poster at ASCO 2023 on Phase 2 EVANGELINE study - https://lnkd.in/eWZ2VVJf

NASDAQ:ATOS

Atossa Therapeutics Inc.

Last Close

1.41

24/09 20:00

Market Cap

174.80M

Beta: 1.17

Volume Today

603

Avg: 329.65K

PE Ratio

−3.72

PFCF: −5.28

Analysis Not Available